129 related articles for article (PubMed ID: 33423777)
1. Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Ben Nasr S; Zribi A; Ben Hassen M; Doghri Y; Ben Abdallah I; Trigui E; Fendri S; Ayari J; Balti M; Haddaoui A
Bull Cancer; 2021 Mar; 108(3):266-271. PubMed ID: 33423777
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
Yorulmaz A; Dogan M; Artuz F; Zengin N
Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.
Lin YC; Chang HK; Chen JS; Wang HM; Yang TS; Liaw CC
Jpn J Clin Oncol; 2007 Jan; 37(1):23-9. PubMed ID: 17172351
[TBL] [Abstract][Full Text] [Related]
5. Options for primary chemotherapy of epithelial ovarian cancer: taxanes.
Trimble EL; Arbuck SG; McGuire WP
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S114-21. PubMed ID: 7835794
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
Hsu Y; Sood AK; Sorosky JI
Am J Clin Oncol; 2004 Feb; 27(1):14-8. PubMed ID: 14758127
[TBL] [Abstract][Full Text] [Related]
8. Dermatological adverse events with taxane chemotherapy.
Sibaud V; Lebœuf NR; Roche H; Belum VR; Gladieff L; Deslandres M; Montastruc M; Eche A; Vigarios E; Dalenc F; Lacouture ME
Eur J Dermatol; 2016 Oct; 26(5):427-443. PubMed ID: 27550571
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.
Poi MJ; Berger M; Lustberg M; Layman R; Shapiro CL; Ramaswamy B; Mrozek E; Olson E; Wesolowski R
Support Care Cancer; 2013 Oct; 21(10):2679-86. PubMed ID: 23686402
[TBL] [Abstract][Full Text] [Related]
11. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
13. Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancer.
Warm M; Nawroth F; Ohlinger R; Valter M; Pantke E; Mallmann P; Harbeck N; Kates R; Thomas A
Onkologie; 2007 Sep; 30(8-9):436-41. PubMed ID: 17848815
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Omlin A; Sartor O; Rothermundt C; Cathomas R; De Bono JS; Shen L; Su Z; Gillessen S
Clin Genitourin Cancer; 2015 Aug; 13(4):e205-e208. PubMed ID: 25733056
[TBL] [Abstract][Full Text] [Related]
15. Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma.
Liu SL; Sun XS; Li XY; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Yan JJ; Lin C; Yang ZC; Tang LQ; Guo L; Mai HQ
BMC Cancer; 2018 Dec; 18(1):1279. PubMed ID: 30572856
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
